XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 21,687,480 $ 14,310,862
Short-term investments 63,117,288 130,982,913
Accounts receivable from affiliated entities 1,862,739 2,405,228
Prepaid expenses and other current assets 4,617,116 5,393,665
Prepaid expenses and other current assets from affiliated entity 0 20,432
Total current assets 91,284,623 153,113,100
Fixed assets, net 4,091,562 4,960,986
Investment in affiliated entity 2,644,226 2,780,287
Operating lease right-of-use assets 8,472,848 9,491,735
Other assets 566,415 605,315
Total assets 107,059,674 170,951,423
Current liabilities:    
Accrued clinical trial expenses 4,496,568 2,365,382
Operating lease liability 2,425,112 2,406,522
Grant funding liability 0 87,489
Grant funding liability from affiliated entity 0 21,918
Convertible senior notes 0 16,770,654
Total current liabilities 23,499,137 42,570,228
Operating lease liability, net of current portion 10,020,227 11,032,066
Total liabilities 33,519,364 53,602,294
Stockholders’ equity:    
Preferred stock 0 0
Common stock 26,051 22,792
Additional paid-in capital 1,784,975,303 1,740,954,074
Accumulated deficit (1,710,837,583) (1,622,965,136)
Accumulated other comprehensive loss (623,461) (662,601)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 73,540,310 117,349,129
Total liabilities and stockholders’ equity 107,059,674 170,951,423
Nonrelated Party    
Current liabilities:    
Accounts payable and accrued expenses 14,743,191 19,847,744
Related Party    
Current liabilities:    
Accounts payable and accrued expenses $ 1,834,266 $ 1,070,519